Skip to main content

Table 4 Years of potential life lost (YPLL) stratified by selected characteristics among patients with ATTR-CM compared to an age and sex-matched general population (years)

From: Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis

  No. of patients No. of death, n (%) Age at diagnosis, mean (SD) Age at death, mean (SD) YPLL (years), mean (SD)
Total 175 62 (35.4) 75.2 (10.6) 75.9 (10.5) 13.0 (7.7)
Age group (years)
 < 65 48 9 (18.8) 56.8 (3.8) 57.8 (4.3) 27.4 (5.0)
 ≥ 65 127 53 (41.7) 78.3 (7.8) 79.0 (7.7) 10.5 (4.8)
Sex
 Male 110 38 (34.5) 75.1 (10.9) 76.0 (10.7) 12.0 (7.0)
 Female 65 24 (36.9) 75.3 (10.3) 75.9 (10.3) 14.6 (8.6)
CCI
 < 3 87 21 (24.1) 69.9 (11.3) 71.1 (11.2) 16.4 (9.2)
 ≥ 3 88 41 (46.6) 77.9 (9.2) 78.4 (9.2) 11.2 (6.2)
History of diseases
 Cardiac manifestation
  Hypertension 90 33 (36.7) 77.2 (8.3) 77.9 (8.4) 11.5 (5.9)
  Atrial fibrillation 36 13 (36.1) 78.3 (8.6) 79.1 (8.2) 10.6 (4.5)
  Other cardiovascular disease 95 36 (37.9) 75.3 (11.2) 76.1 (11.1) 13.5 (8.4)
 Non-cardiac manifestation
  Musculoskeletal disease 119 52 (43.7) 76.3 (10.4) 77.1 (10.2) 12.3 (7.3)
  Depression, anxiety, insomnia 77 34 (44.2) 75.9 (9.9) 76.6 (9.8) 12.8 (7.4)
  Peripheral neuropathy 59 29 (49.2) 75.7 (8.8) 76.4 (8.5) 12.8 (6.5)
  Diabetes mellitus 57 22 (38.6) 75.7 (9.1) 76.5 (9.3) 12.7 (7.3)
  Malignancy 17 5 (29.4) 83.4 (3.1) 84.4 (2.5) 7.4 (1.8)
  Dementia 9 9 (100.0) 83.6 (7.7) 83.9 (7.6) 7.9 (3.7)
  1. ATTR-CM Transthyretin amyloid cardiomyopathy, CCI Charlson comorbidity index, SD Standard deviation, YPLL Years of potential life lost